A look at how tapping real world evidence from medical devices and patients could be a game changer, improving patient-clinician communication, supporting earlier interventions and helping patients manage their condition.
Innovative approaches to real world evidence collection present opportunities for medical device companies to improve patient outcomes. But success will depend on improving the way medtech companies integrate digital health. Executives from Abbott, Smith & Nephew, AliveCor and Huma weigh in on these issues.
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
The justices ruled that the authority of the judges of the Patent Trial and Appeal Board is unconstitutional, but by giving the USPTO director greater oversight, the highest court likely saved this favored tool of generic patent challengers.
The acquisition price for the Israeli company was $110 million in upfront cash payments with the potential for an additional $110 million upon meeting certain commercial milestones.
If you’re the midnight tinkerer carrying around the design for a medical device, be sure to apply for the Massachusetts Medical Device Development Center-M2D2 New Venture Competition by Feb. 10. The first-, second- and third-place winners will divvy up $50,000 worth of services from University of Massachusetts incubator M2D2, Smith & Nephew and Nutter McClennen […]
Smith & Nephew‘s (NYSE:SNN) spinoff of its biologics and clinical therapies operation into a joint venture will keep the business at its present location in Durham, North Carolina. But the unit, which will be majority owned by life sciences investing firm Essex Woodlands, will operate under the new name Bioventus. London-based medical technology giant Smith […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Smith & Nephew (NYSE:SNN) executive Mark Augusti takes time to occasionally talk to students about his experience in medical devices and his thoughts on the industry. Often he’s asked if the industry that he’s made his career will be a good one in the future. “I think it will be,” he said. “But it will […]
British orthopedic giant Smith & Nephew plc (NYSE:SNN) announced an ambitious plan to realign the entire company to focus growth on the emerging markets of Brazil, Russia, India and China, while creating a more streamlined operation in its existing markets. Bouhon said the moves will be made with the intention of growing the company’s sales […]
The world’s largest asset management firm, BlackRock Inc., boosts its position in Smith & Nephew to nearly 45 million shares, making it the orthopedic company’s largest institutional shareholder. BlackRock Inc. (NYSE:BLK) increased stake in British orthopedic device maker Smith & Nephew plc (NYSE:SNN) by some 2 million shares, making it the company’s single largest investor. […]
Smith & Nephew plc reportedly spurns a $10.9 billion buyout offer from Johnson & Johnson; Biomet, Stryker and Zimmer could also be players in the action. Smith & Nephew plc (NYSE:SNN) shares jumped nearly 12 percent on news that it spurned a $10.9 billion buyout bid from Johnson & Johnson (NYSE:JNJ), according to Sky News […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
As the history of social legislation suggests -- and as this week's federal court ruling on the so-called individual mandate makes clear, the effects of healthcare reform on our politics may not be settled until a lot of President Obama's aides are collecting Medicare checks, according to the New York Times.
Smith & Nephew plc’s (NYSE:SNN) attempt to derail a former employee’s False Claims Act suit alleging that it lied about the origins of its products was rejected yesterday. The United Kingdom-based medical device maker attempted to have the suit dismissed for “lack of subject matter jurisdiction” and “failure to state a claim,” contending that the […]